本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Can-Fite Biopharma Ltd

3.22
-0.0699-2.12%
成交量:1.83萬
成交額:5.87萬
市值:689.92萬
市盈率:0.00
高:3.29
開:3.25
低:3.20
收:3.29
52周最高:36.40
52周最低:3.11
股本:214.25萬
流通股本:210.50萬
量比:1.48
換手率:0.87%
股息:- -
股息率:- -
每股收益(TTM):-2,665.2840
每股收益(LYR):-3,259.3317
淨資產收益率:-264.12%
總資產收益率:-81.86%
市淨率:1.65
市盈率(LYR):0.00

資料載入中...

2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/11

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/04

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/13

SEC問詢函

CORRESP [Cover] - Correspondence
2021/08/26

招股説明書

Can-Fite BioPharma Ltd.
2021/08/26

招股説明書

F-1 - Registration statement for certain foreign private issuers
2021/03/25

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/09

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/01/29

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/11/30

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/10/07

SEC問詢函

CORRESP [Cover] - Correspondence
2020/08/27

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/07/22

SEC問詢函

CORRESP [Cover] - Correspondence
2020/07/10

招股説明書

F-1 - Registration statement for certain foreign private issuers
2020/06/19

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/19

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/06/01

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/13

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/07

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]